Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document iptacopan - CFB inhibitor Company overview Financial review Conclusions Appendix NCT03955445 (CLNP023B12001B) iptacopan - CFB inhibitor NCT04817618 APPEAR-C3G (CLNP023B12301) C3 glomerulopathy Phase 3 Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection) Experimental: iptacopan 200mg b.i.d. Placebo Comparator: Placebo to iptacopan 200mg b.i.d. Patients with native C3G Indication C3 glomerulopathy (C3G) Indication Phase Phase 2 Phase Patients 27 patients from ongoing Ph2 (sample size from Ph3 pending HA discussions Q1 2021), total patients for this study will increase Patients 83 Arms Intervention Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Open-label LNP023 200mg bid Primary Outcome Measures Arms Intervention Target Patients Target Patients Readout Patients with C3 glomerulopathy 2025 Readout Milestone(s) 2023 Primary Innovation: Pipeline overview Outcome Measures Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic Immunology Neuroscience Oncology Other Global Health Abbreviations References Milestone(s) Publication TBD Publication TBD □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 49

View entire presentation